Editas Medicine to Participate in Investor Conferences in October

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October.  Details are as follows:

Chardan Gene Therapy ConferenceTuesday, October 10

• Manufacturing Panel | 12:15 p.m. ET
• Fireside Chat | 3:45 p.m. ET

Jefferies Gene Technology Investor SummitThursday, October 12

• Presentation | 1:20 p.m. ET

A live webcast of the events will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the events.                                          About Editas MedicineEditas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.  The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Media Contact Cristi Barnett
 Editas Medicine, Inc.(617) 401-0113[email protected]

Investor ContactMark MullikinEditas Medicine, Inc.(617) 401-9083[email protected]

You May Also Be Interested In

• Toys"R"Us Asia Leads the Return to Play
• IceBull’s 1250X Potential Takes Center Stage While Buyers Can Still Access the Opening Presale Price
• Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million